”The main priority in our commercial efforts right now is to grow the user base, and we are clearly seeing that our ability to generate new customers is better than ever. In fact, during the first two quarters of 2022, we have already had as many customers (66) as we had for the full year 2021. Volumes will increase with each customer as pandemic-related backlogs are worked through and when user experience from the Episealer® increases”, says Pål Ryfors, CEO Episurf Medical.

Second quarter 2022 compared to 2021, Group

• Gross order intake amounted to SEK 2.0m (1.4)
• Order book amounted to SEK 1.5m (1.3)
• Group net sales amounted to SEK 1.9m (2.0)
• Loss for the period amounted to SEK -19.4m (-17.7)
• Earnings per share amounted to SEK -0.07(-0.08)

First six months 2022 compared to 2021, Group

• Gross order intake amounted to SEK 3.6m (3.6)
• Group net sales amounted to SEK 3.4m (3.6)
• Loss for the period amounted to SEK -35.8m (-34.4)
• Earnings per share amounted to SEK -0.13(-0.16)

Significant events during the second quarter

• Promising results from comparative study with Episealer® were accepted for presentation at German orthopaedic congress
• Episurf Medical submitted follow-up 510(k) application for Episealer® Patellofemoral System that is now under substantive review at the US FDA
• Prospective investigator-initiated study for 2 years’ follow-up of Episealer® Talus patient initiated
• First knee implant Episealer® surgery was planned in Saudi Arabia, and India were planned
• First Episealer® Talus surgery performed in Portugal and Belgium
• 5-year follow-up data presented at several clinical congresses

Significant events after the second quarter

• Presentation by Prof Karl Eriksson about the Episealer® Knee technology and clinical results at the 5th International Conference on Meniscus Science and Surgery in Luxembourg